Moleculin Biotech, Inc.
MBRX
$2.34
-$0.10-4.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 144.39% | -358.59% | -18.71% | 2.25% | 35.29% |
| Total Depreciation and Amortization | -59.09% | -21.43% | -9.68% | 0.00% | -3.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -177.35% | 1,146.77% | 108.37% | 167.69% | -87.89% |
| Change in Net Operating Assets | 210.86% | -405.97% | -147.45% | -32.50% | 98.11% |
| Cash from Operations | 25.71% | -29.40% | -22.30% | 10.21% | 16.85% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17.57% | 17.55% | -32.20% | 799,800.00% | -99.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17.44% | 17.55% | -32.20% | 799,800.00% | -99.98% |
| Foreign Exchange rate Adjustments | 1,000.00% | -- | -100.00% | 106.67% | -421.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 354.68% | -437.11% | -104.62% | 167.06% | -256.04% |